BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

AN2 Therapeutics (ANTX)AN2 TherapeuticsConference / presentation

MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2025-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom , Co-Founder, Chairman,

Open original release

Related news

ANTXAN2 Therapeutics2026-02-17 12:00 EST

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

SPROSpero Therapeutics2024-05-16 16:05 EST

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

SPROSpero Therapeutics2024-02-26 08:05 EST

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

AVIRAtea2025-11-19 12:00 EST

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

OGENOragenics2026-05-19 12:45 EST

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

ASMBAssembly Biosciences2026-05-11 12:00 EST

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

View all latest news

AN2 Therapeutics

AN2 Therapeutics is an infectious-disease company focused on novel anti-infective medicines. Its platform is aimed at serious bacterial and related infectious conditions where new options matter.

Recent company news

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

ANTXAN2 Therapeutics2026-05-21 11:00 EST

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-05-07 20:01 EST

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

ANTXAN2 Therapeutics2026-03-31 11:00 EST

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

Stock data

Close
4.93 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States